Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

James Croft, BSc, MBBS, MRCP, Andrew Hall, Katrina Walker, Amy L Sherborne, PhD, Kevin Boyd, Mamta Garg, Charlotte Pawlyn, BA, PhD MBBChir, MRCP, FRCPath, Debbie Sherratt, Sadie Reed, PhD, William E Pierceall, Gordon Cook, Anjan Thakurta, PhD, Sarah R Brown, PhD MSc, BSc, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2018-99-111823

Published: 2018

Journal Articles

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Ruth M De Tute, BSc,MSc, Debbie Sherratt, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 802.

https://doi.org/10.1182/blood-2018-99-116426

Published: 2018

Journal Articles

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 3280.

https://doi.org/10.1182/blood-2018-99-118868

Published: 2018

Journal Articles

Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS- mutant Multiple Myeloma

Priya Sriskandarajah, MBBS, BSc, MRCP, Kevin Boyd, Wen Xu, MD, Irene Moreno Candilejo, MD, Sidra Ellis, Amy Price, Amy L Sherborne, PhD, James Croft, MBBS, BSc, Vallari Shah, MBBS, Joanna Dawes, PhD, Mona Parmar, Alison Turner, Emma Hall, BSc, MSc, PhD, Nina Tunariu, MBBS, MDes, MRCP, FRCR, Juanita S Lopez, MB BChir, MRCP, PhD, Johann S. de Bono, Udai Banerji, MBBS, MD DNB, PhD FRCP, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 3237.

https://doi.org/10.1182/blood-2018-99-111821

Published: 2018

Journal Articles

Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

James Croft, BSc, MBBS, MRCP, Andrew Hall, Katrina Walker, Amy L Sherborne, PhD, Sidra Ellis, Amy Price, Debbie Sherratt, Sadie Reed, PhD, Charlotte Pawlyn, BA, PhD MBBChir, MRCP, FRCPath, Mamta Garg, Kevin Boyd, Gordon Cook, Sarah R Brown, PhD MSc, BSc, Martin Kaiser, MD

Blood (2018) 132 (Supplement 1): 3274.

https://doi.org/10.1182/blood-2018-99-111835

Published: 2018

Journal Articles

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Debbie Sherratt, Jessica Kendall, BSc, MSc, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Ruth M De Tute, BSc,MSc, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 306.

https://doi.org/10.1182/blood-2018-99-116624

Published: 2018

Journal Articles

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Blood (2018) 132 (Supplement 1): 302.

https://doi.org/10.1182/blood-2018-99-114956

Published: 2018

Journal Articles

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Blood (2018) 132 (Supplement 1): 301.

https://doi.org/10.1182/blood-2018-99-112079

Published: 2018

Journal Articles

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 122.

https://doi.org/10.1182/blood-2018-99-111117

Published: 2018

Journal Articles

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Blood (2018) 132 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2018-99-110149

Published: 2018

Journal Articles

Downregulation Of The Wnt Inhibitor CXXC5 Predicts a Better Prognosis In Acute Myeloid Leukemia

Blood (2013) 122 (21): 52.

https://doi.org/10.1182/blood.V122.21.52.52

Published: 2013

Journal Articles

Improved Risk Stratification in Myeloma Using Microrna-Based Classifier

Ping Wu, MBBS, MSc, Luca Agnelli, PhD, Brian A Walker, BSc, PhD, Katia Todoerti, David C Johnson, PhD, Martin Kaiser, MD, Christopher P Wardell, PhD, Walter M Gregory, PhD, Faith E. Davies, MD, Daniel Brewer, PhD, Antonino Neri, Gareth J. Morgan, MD PhD

Blood (2012) 120 (21): 932.

https://doi.org/10.1182/blood.V120.21.932.932

Published: 2012

Journal Articles

Decrease in CD4+ T Cells in Multiple Myeloma Patients Receiving Bortezomib.

Ulrike Heider, MD, Jessica Rademacher, MD, Martin Kaiser, MD, Ivana von Metzler, MD, Karin Marquardt, Orhan Sezer, MD, PhD

Blood (2009) 114 (22): 3865.

https://doi.org/10.1182/blood.V114.22.3865.3865

Published: 2009

Journal Articles

An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma.

Christian Jakob, MD,, Theresa Wernecke, MD, Jan Sterz, MD, Andrea Goerke, MD, Ulrike Heider, MD, Martin Kaiser, MD, Maren Mieth, PhD, Susanne Ziefle, MD, Orhan Sezer, MD, PhD

Blood (2009) 114 (22): 2802.

https://doi.org/10.1182/blood.V114.22.2802.2802

Published: 2009

Journal Articles

Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Group Which Has No Benefit from High-Dose Therapy

Christian Jakob, MD, Peter Liebisch, MD, Ulrike Heider, MD, Martin Kaiser, MD, Jan Sterz, MD, Jessica Rademacher, MD, Claudia Fleissner, MD, Christian Müller, MD, Orhan Sezer, MD

Blood (2008) 112 (11): 2721.

https://doi.org/10.1182/blood.V112.11.2721.2721

Published: 2008

Journal Articles

The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.

Christian Jakob, MD, Peter Liebisch, MD, Karl Egerer, MD, Jan Sterz, MD, Martin Kaiser, MD, Susanne Rötzer, MD, Ulrike Heider, MD, Jessica Rademacher, MD, Claudia Fleissner, MD, Peter M. Kloetzel, PhD, Evangelos Terpos, MD, Orhan Sezer, MD

Blood (2007) 110 (11): 1475.

https://doi.org/10.1182/blood.V110.11.1475.1475

Published: 2007

Journal Articles

A Novel Notch Pathway Inhibitor Blocks Osteoclast Activity and Synergistically Induces Apoptosis with the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cells.

Franziska Jundt, MD, Rolf Schwarzer, Phd, Martin Kaiser, MD, Oezlem Acikgoez, MD, Ulrike Heider, MD, Stephan Mathas, MD, Robert Preissner, Phd, Orhan Sezer, MD, Bernd Dorken, MD

Blood (2007) 110 (11): 1522.

https://doi.org/10.1182/blood.V110.11.1522.1522

Published: 2007

Journal Articles

Serum Concentrations of DKK-1 Correlate with the Extent of Bone Disease in Multiple Myeloma.

Martin Kaiser, MD, Maren Mieth, PhD, Peter Liebisch, MD, PhD, Susanne Rötzer, Christian Jakob, MD, Claudia Fleissner, MD, Edgar Braendle, MD, PhD, David Stover, PhD, Malte Peters, MD, PhD, Orhan Sezer, MD, PhD, Ulrike Heider, MD

Blood (2007) 110 (11): 3518.

https://doi.org/10.1182/blood.V110.11.3518.3518

Published: 2007

Journal Articles

The Proteasome Inhibitor BSc2118 Causes Growth Inhibition, Cell Cycle Arrest and Cyclin D1 Degradation in Mantle Cell Lymphoma Cell Lines.

Christian Jakob, MD, Jan Sterz, MD, Ivana von Metzler, MD, Ulrike Kuckelkorn, PhD, Hannes A. Braun, PhD, Susanne Rötzer, MD, Martin Kaiser, MD, Ulrike Heider, MD, Jessica Rademacher, MD, Peter M. Kloetzel, PhD, Orhan Sezer, MD

Blood (2007) 110 (11): 1401.

https://doi.org/10.1182/blood.V110.11.1401.1401

Published: 2007

Journal Articles

Synergistic Interaction of the Histone Deacetylase Inhibitor SAHA with the Proteasome Inhibitor Bortezomib in Mantle Cell Lymphoma.

Ulrike Heider, MD, Martin Kaiser, MD, Ivana Zavrski, MD, Jan Sterz, MD, Christian Jakob, MD, Claudia Fleissner, MD, Monica Hecht, MD, Lorenz Kleeberg, MD, Christian Braun, MD, Kurt Possinger, MD, Orhan Sezer, MD

Blood (2006) 108 (11): 2509.

https://doi.org/10.1182/blood.V108.11.2509.2509

Published: 2006

NARROW

Cyclophosphamide Exerts Significant Immunomodulatory Function in Myeloma Patients Treated with Pomalidomide and Dexamethasone

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial

Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS- mutant Multiple Myeloma

Cyclophosphamide, Pomalidomide and Dexamethasone Significantly Improves Response over Poma/Dex in Relapsed/Refractory Myeloma Patients Previously Treated with Cyclophosphamide Combination Therapy - Initial Results of the Randomised Multicentre Mukseven Trial

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

A Quadruplet Regimen Comprising Carfilzomib, Cyclophosphamide, Lenalidomide, Dexamethasone (KCRD) Vs an Immunomodulatory Agent Containing Triplet (CTD/CRD) Induction Therapy Prior to Autologous Stem Cell Transplant: Results of the Myeloma XI Study

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Downregulation Of The Wnt Inhibitor CXXC5 Predicts a Better Prognosis In Acute Myeloid Leukemia

Improved Risk Stratification in Myeloma Using Microrna-Based Classifier

Decrease in CD4+ T Cells in Multiple Myeloma Patients Receiving Bortezomib.

An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma.

Incorporation of the Bone Marker Carboxy-Terminal Telopeptide of Type-1 Collagen (ICTP) into a Combined ISS-ICTP Score Improves the Prognostic Significance of the ISS in Newly Diagnosed Symptomatic Multiple Myeloma and Identifies a Very Low Risk Group Which Has No Benefit from High-Dose Therapy

The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.

A Novel Notch Pathway Inhibitor Blocks Osteoclast Activity and Synergistically Induces Apoptosis with the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cells.

Serum Concentrations of DKK-1 Correlate with the Extent of Bone Disease in Multiple Myeloma.

The Proteasome Inhibitor BSc2118 Causes Growth Inhibition, Cell Cycle Arrest and Cyclin D1 Degradation in Mantle Cell Lymphoma Cell Lines.

Synergistic Interaction of the Histone Deacetylase Inhibitor SAHA with the Proteasome Inhibitor Bortezomib in Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only